1. Home
  2. FNWD vs TLSA Comparison

FNWD vs TLSA Comparison

Compare FNWD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

N/A

Current Price

$36.51

Market Cap

147.7M

Sector

Finance

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.98

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
TLSA
Founded
1994
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.7M
155.3M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
FNWD
TLSA
Price
$36.51
$0.98
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$37.50
N/A
AVG Volume (30 Days)
28.8K
199.2K
Earning Date
04-28-2026
05-04-2026
Dividend Yield
1.51%
N/A
EPS Growth
N/A
N/A
EPS
0.52
N/A
Revenue
N/A
N/A
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$70.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$0.99
52 Week High
$39.99
$2.60

Technical Indicators

Market Signals
Indicator
FNWD
TLSA
Relative Strength Index (RSI) 62.65 36.47
Support Level $36.37 N/A
Resistance Level $38.86 $1.45
Average True Range (ATR) 0.94 0.12
MACD -0.04 -0.02
Stochastic Oscillator 33.66 17.78

Price Performance

Historical Comparison
FNWD
TLSA

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: